Sort   by:  
 Page size 
Comparison of long-lived daf-2 pathway mutants with wild type/short-lived mutants. A: age-1 fer-15; fem-1 vs. fer-15; fem-1. B: age-1 fer-15; fem-1 vs. fer-15; fem-1. C: fer-15; daf-2(mu150); fem-1 vs. fer-15; fem-1. D: fer-15; daf-2(mu150); fem-1 vs. fer-15; fem-1. E: daf-16::gfp in daf...
ORGANISM(S): Caenorhabditis elegans 
Paper title: Navigating through chemical space and evolutionary time across the Australian continent in plant genus Eremophila. Author List: Oliver Gericke, Rachael M. Fowler, Allison M. Heskes, Michael J. Bayly, Susan J. Semple, Chi P. Ndi, Dan Stark, Claus J. Loland, Daniel J. Murphy, Bevan J....
ORGANISM(S): Eremophila <angiosperm> (ncbitaxon:255893) Diocirea Bontia Daphnoides (ncbitaxon:255891) Myoporum (ncbitaxon:57115) Calamphoreus Inflatus Myoporeae (ncbitaxon:216811) Glycocystis 
2020-12-29 | MSV000086644 | GNPS
Comparison of sterile worms grown on Control Vector, daf-2 RNAi, and daf-2 + daf-16 RNAi. Synchronized fer-15(b26); fem-1(hc17) animals were grown on RNAi bacteria at 25ºC, induced with IPTG on Day 1 of adulthood, and collected from 0-48 hours (10 time points) and 0-196 hours (10 time points); RNAi ...
ORGANISM(S): Caenorhabditis elegans 
Comparison of sterile worms grown on Control Vector, daf-2 RNAi, and daf-2 + daf-16 RNAi. Synchronized fer-15(b26); fem-1(hc17) animals were grown on RNAi bacteria at 25ºC, induced with IPTG on Day 1 of adulthood, and collected from 0-48 hours (10 time points) and 0-196 hours (10 time points); RNAi ...
ORGANISM(S): Caenorhabditis elegans 
Gene expression changes caused by estrogen treatment of breast cancer cells that re-express ERalpha was investigated by infecting ER-negative MDA-MB-231 breast cancer cells for 24 h with recombinant adenovirus encoding full-length human ERalpha (Ad-ERalpha) or control vector (Ad-LacZ), and treating ...
ORGANISM(S): Homo sapiens 
Inorganic nitrate (NO3-) has been proposed to be of therapeutic use as a dietary supplement in obesity and related conditions including the Metabolic Syndrome (MetS), type-II diabetes and metabolic dysfunction associated steatotic liver disease (MASLD). Administration of NO3- to endothelial nitric o...
2025-07-14 | MTBLS9526 | MetaboLights
Sort   by:  
 Page size